Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins
- PMID: 8823312
- PMCID: PMC507573
- DOI: 10.1172/JCI118934
Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins
Abstract
Aggregation and retention of LDL in the arterial wall are key events in atherogenesis, but the mechanisms in vivo are not known. Previous work from our laboratories has shown that exposure of LDL to bacterial sphingomyelinase (SMase) in vitro leads to the formation of LDL aggregates that can be retained by extracellular matrix and that are able to stimulate macrophage foam cell formation. We now provide evidence that retained LDL is hydrolyzed by an arterial-wall SMase activity. First, we demonstrated that SMase-induced aggregation is caused by an increase in particle ceramide content, even in the presence of excess sphingomyelin (SM). This finding is compatible with previous data showing that lesional LDL is enriched in SM, though its ceramide content has not previously been reported. To address this critical compositional issue, the ceramide content of lesional LDL was assayed and, remarkably, found to be 10-50-fold enriched compared with plasma LDL ceramide. Furthermore, the ceramide was found exclusively in lesional LDL that was aggregated; unaggregated lesional LDL, which accounted for 20-25% of the lesional material, remained ceramide poor. When [3H]SM-LDL was incubated with strips of rabbit aorta ex vivo, a portion of the LDL was retained, and the [3H]SM of this portion, but not that of unretained LDL, was hydrolyzed to [3H]ceramide by a nonlysosomal arterial hydrolase. In summary, LDL retained in atherosclerotic lesions is acted upon by an arterial-wall SMase, which may participate in LDL aggregation and possibly other SMase-mediated processes during atherogenesis.
Similar articles
-
Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development.J Biol Chem. 1998 Jan 30;273(5):2738-46. doi: 10.1074/jbc.273.5.2738. J Biol Chem. 1998. PMID: 9446580
-
Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix.Arterioscler Thromb Vasc Biol. 1999 Nov;19(11):2648-58. doi: 10.1161/01.atv.19.11.2648. Arterioscler Thromb Vasc Biol. 1999. PMID: 10559007
-
Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation.J Biol Chem. 1993 Sep 25;268(27):20419-32. J Biol Chem. 1993. PMID: 8376399
-
Sphingomyelinase activity of LDL: a link between atherosclerosis, ceramide, and apoptosis?Trends Cardiovasc Med. 2002 Jan;12(1):37-42. doi: 10.1016/s1050-1738(01)00143-8. Trends Cardiovasc Med. 2002. PMID: 11796243 Review.
-
Neutral sphingomyelinase.Adv Lipid Res. 1993;26:25-48. Adv Lipid Res. 1993. PMID: 8379453 Review.
Cited by
-
Characterization of secretory sphingomyelinase activity, lipoprotein sphingolipid content and LDL aggregation in ldlr-/- mice fed on a high-fat diet.Biosci Rep. 2012 Oct;32(5):479-90. doi: 10.1042/BSR20120036. Biosci Rep. 2012. PMID: 22712892 Free PMC article.
-
Sphingolipid metabolism and signaling in cardiovascular diseases.Front Cardiovasc Med. 2022 Aug 31;9:915961. doi: 10.3389/fcvm.2022.915961. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36119733 Free PMC article. Review.
-
Variation in Coronary Atherosclerosis Severity Related to a Distinct LDL (Low-Density Lipoprotein) Profile: Findings From a Familial Hypercholesterolemia Pig Model.Arterioscler Thromb Vasc Biol. 2019 Nov;39(11):2338-2352. doi: 10.1161/ATVBAHA.119.313246. Epub 2019 Sep 26. Arterioscler Thromb Vasc Biol. 2019. PMID: 31554418 Free PMC article.
-
Lipidomics in Understanding Pathophysiology and Pharmacologic Effects in Inflammatory Diseases: Considerations for Drug Development.Metabolites. 2022 Apr 7;12(4):333. doi: 10.3390/metabo12040333. Metabolites. 2022. PMID: 35448520 Free PMC article. Review.
-
The formation and consequences of cholesterol-rich deposits in atherosclerotic lesions.Front Cardiovasc Med. 2023 Feb 28;10:1148304. doi: 10.3389/fcvm.2023.1148304. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36926046 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources